Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (101-110 of 263) with videos related to

Pageof 27
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJean-Pierre J Issa, Vazganush Gharibyan, Jorge Cortes, et al.
Tomography (Ann Arbor, Mich.)|May 24, 2016
A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in MyelofibrosisGary D Luker, Huong Marie Nguyen, Benjamin A Hoff, et al.
Cellular Signalling|August 23, 2011
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitinationVaibhav Kapuria, Alexander Levitzki, William G Bornmann, et al.
Cancer|March 8, 2007
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureHagop Kantarjian, Susan O'Brien, Moshe Talpaz, et al.
Blood|July 29, 2011
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemiaPeter Ouillette, Roxane Collins, Sajid Shakhan, et al.
The Lancet. Haematology|April 11, 2024
Methodological challenges in the development of endpoints for myelofibrosis clinical trialsGiovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Pregnancy among patients with chronic myeloid leukemia treated with imatinibPatricia Ault, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Pageof 27

Showing results (101-110 of 263) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylateJean-Pierre J Issa, Vazganush Gharibyan, Jorge Cortes, et al.
Tomography (Ann Arbor, Mich.)|May 24, 2016
A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in MyelofibrosisGary D Luker, Huong Marie Nguyen, Benjamin A Hoff, et al.
Cellular Signalling|August 23, 2011
A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitinationVaibhav Kapuria, Alexander Levitzki, William G Bornmann, et al.
Cancer|March 8, 2007
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failureHagop Kantarjian, Susan O'Brien, Moshe Talpaz, et al.
Blood|July 29, 2011
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemiaPeter Ouillette, Roxane Collins, Sajid Shakhan, et al.
The Lancet. Haematology|April 11, 2024
Methodological challenges in the development of endpoints for myelofibrosis clinical trialsGiovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
Blood|October 24, 2002
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|July 2, 2003
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implicationsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Pregnancy among patients with chronic myeloid leukemia treated with imatinibPatricia Ault, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia Research|October 18, 2013
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaSimona Soverini, Susan Branford, Franck E Nicolini, et al.
Pageof 27